Colon cancer (adjuvant) - capecitabine and oxaliplatin: review decision - June 2011

Review of NICE Technology Appraisal Guidance No. 100; Colon cancer (adjuvant) - capecitabine and oxaliplatin

The Institute was proposing that the technology appraisal should be incorporated into the on-going clinical guideline of the diagnosis and management of colorectal cancer (publication anticipated October 2011).

During consultation, the majority of comments received by the Institute agreed with the proposal put forward. After consideration of all of the comments (attached as appendix A), the Institute’s Guidance Executive has decided to proceed with the proposal.

June 2011

This page was last updated: 04 July 2011

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.

Selected, reliable information for health and social care in one place

Accessibility | Cymraeg | Freedom of information | Vision Impaired | Contact Us | Glossary | Data protection | Copyright | Disclaimer | Terms and conditions

Copyright 2014 National Institute for Health and Care Excellence. All rights reserved.